|1.||Romano, Suzanne J: 1 article (01/2005)|
|2.||Blume, E D: 1 article (09/2000)|
|3.||Nelson, D P: 1 article (09/2000)|
|4.||Mayer, J E: 1 article (09/2000)|
|5.||Phillips, L: 1 article (09/2000)|
|6.||Schermerhorn, M L: 1 article (09/2000)|
09/01/2000 - "In isolated neonatal lamb hearts that underwent hypothermic cardioplegic ischemia, CY-1503 administration reduced myocardial neutrophil accumulation and preserved endothelial and contractile function. "
09/01/2000 - "CY-1503 (40 mg/L) or saline vehicle was added to blood perfusate before ischemia. "
11/01/1994 - "Our results provide strong evidence that treatment with a unique carbohydrate analog of SLeX, CY-1503, significantly reduces the degree of myocardial injury associated with coronary artery ischemia and reperfusion. "
01/01/1999 - "The impaired myocardial contractile function after ischemia and cardioplegia was not improved by administration of CY-1503. "
09/01/2000 - "The efficacy of CY-1503 to attenuate global myocardial reperfusion injury was assessed in isolated blood-perfused neonatal lamb hearts that had 2 hours of cold cardioplegic ischemia. "
08/01/1996 - "We conclude that CY-1503 does not substantially or consistently reduce myocardial infarct size or neutrophil accumulation in dogs subjected to ischemia followed by a prolonged period (48 hours) of reperfusion."
08/01/1995 - "The purpose of the present study was to assess the efficacy of a selectin blocker (CY 1503) given as an adjunct to thrombolytic therapy to interfere with the inflammatory response after ischemia-reperfusion and subsequently reduce myocardial infarct size in the electrolytic canine model. "
|4.||Myocardial Reperfusion Injury
01/01/2005 - "Cytel's CY 1503, a complex oligosaccharide, progressed to phase II/III trials for reperfusion injury, but further development was halted when it failed to demonstrate clinical efficacy. "
10/01/1997 - "We evaluated the inhibitory effect of CY-1503 on PMN migration and reperfusion injury in canine left lung allografts. "
10/01/1997 - "Carbohydrate selectin inhibitor CY-1503 reduces neutrophil migration and reperfusion injury in canine pulmonary allografts."
09/01/2000 - "Blockade of selectin-mediated neutrophil-endothelial interactions with CY-1503, a synthetic analogue of Sialyl-LewisX, might reduce reperfusion injury after myocardial ischemia. "
03/01/1996 - "The SLe(x) oligosaccharide analog, CY-1503, had an important protective role in hepatic ischemia and reperfusion injury. "
|2.||5- acetylneuraminyl- (2- 3)- galactosyl- (1- 4)- (fucopyranosyl- (1- 3))- N- acetylglucosamine (sialyl Lewis x)
|3.||salicylhydroxamic acid (SHAM)
|4.||Interleukin-1alpha (Interleukin 1 alpha)
|6.||Acetylcholine (Acetylcholine Chloride)
|2.||Induced Heart Arrest (Cardioplegia)
|3.||Cardiopulmonary Bypass (Heart-Lung Bypass)
|4.||Homologous Transplantation (Allograft)